SEQ
  • Bienvenido a la SEQ
    • Junta Directiva
    • Misión, visión y valores
    • Elecciones para la renovación Junta Directiva de la SEQ 2021
    • Estatutos SEQ
    • Colaboradores
    • Hazte socio
    • Contacto
  • Noticias
    • Cursos
    • Agenda de Congresos
    • Sociedades Científicas
    • Revistas Científicas
  • Actividades
    • Reuniones
    • Congresos
    • Cursos de Formación
  • Revista Española de Quimiopterapia
    • Journal info
    • Advance articles
    • Search an issue
    • Submission guidelines
    • Submit a manuscript
  • Documentos
    • Documentos de Consenso
    • Libros y monografías
    • Revista Infección y Vacunas
    • Informes
    • Declaraciones
    • Base de Datos
    • Otros
      • Curiosidades
      • Narraciones Infecciosas
  • Click to open the search input field Click to open the search input field Buscar
  • Menú Menú
Abstract, Abstract 2018

Rev Esp Quimioter 2018; 31(3):227-246

Monoclonal spread of multi-drug resistant CTX-M-15-producing Klebsiella pneumoniae. Impact of measures to control the outbreak

MARÍA ÁNGELES ASENCIO EGEA, MARÍA HUERTAS VAQUERO, CRISTINA MUÑOZ-CUEVAS, JORGE GAITÁN PITERA, ÓSCAR HERRÁEZ CARRERA, PATRICIA ALCÁZAR CARMONA, HUGO DANIEL PATIÑO ORTEGA, MARÍA FRANCO HUERTA, CARMEN ROMÁN ORTIZ, MARÍA CARMEN CONDE GARCÍA, RAFAEL CARRANZA GONZÁLEZ, JOSÉ RAMÓN BARBERÁ, VERÓNICA BAUTISTA SÁNCHEZ

Objective. To describe an outbreak of multi-drug resistant extended-spectrum β-lactamases-producing Klebsiella pneumoniae (MDR-ESBL-KPN) and the impact of measures for its control.
Material and methods. We reviewed the patients´ clinical records with MDR-ESBL-KPN isolation during 2013-2016 with resistance to fluoroquinolones, aminoglycosides, fosfomycin, and nitrofurantoin; susceptible to imipenem, meropenem, colistin, and tigecycline and variable to ertapenem and cotrimoxazole (Vitek-2). The genetic relationship between 35 isolates was established by PFGE and MLST. Control measures were put in place in January 2016.
Results. We detected 269 patients colonized and/or infected by KPN-ESBL-MDR with a common resistance phenotype; the strains studied carried the blaCTX-M-15 gene and formed a single cluster belonging to ST11. The outbreak was detected at the end of 2015, although it began in 2013 in an elderly center. The acquisition source of the strains was: 6% community-acquired, 37% hospital-acquired (76% in internal medicine) and 57% related to long health care facilities (78% of hospitalizations in the last year). Ninety-four percent of patients had at least one underlying disease, 90% received antibiotics previously and 49% had some invasive devices. After the introduction of control measures, the incidence of cases in the quarter was reduced from 29 to 15.
Conclusions. We detected a monoclonal outbreak of MDR-CTX-M-15-KPN in 2015, with predominance of health-care associated cases. The success in the rapid spread of the outbreak was due to the delay in its detection and to the fact that most of the patients had previously received antibiotics. The control measures reduced the number of isolates by 50%.

Rev Esp Quimioter 2018; 31(3):227-246 [Texto completo PDF]

18 mayo, 2018/por Luis Alou
Compartir esta entrada
  • Compartir en Facebook
  • Compartir en X
  • Compartir en LinkedIn
  • Compartir por correo
https://seq.es/wp-content/uploads/2017/10/LOGO-SEQ-800X400.png 0 0 Luis Alou https://seq.es/wp-content/uploads/2017/10/LOGO-SEQ-800X400.png Luis Alou2018-05-18 13:56:332018-05-29 12:22:15Rev Esp Quimioter 2018; 31(3):227-246

REVISTA ESPAÑOLA DE QUIMIOTERAPIA

  • Journal Info
  • Advance Articles
  • Issues
  • Submission guidelines
  • Submit a manuscript

Contacto

Telf.: 913 94 15 12
Email: [email protected]

Política de privacidad

Aviso Legal
Política de Privacidad
Política de Cookies

Tweets by TwitterDev
© Copyright - Sociedad Española de Quimioterapia - Enfold Theme by Kriesi
  • Link to Facebook
  • Link to X
  • Link to LinkedIn
Link to: Rev Esp Quimioter 2018; 31(3):227-246 Link to: Rev Esp Quimioter 2018; 31(3):227-246 Rev Esp Quimioter 2018; 31(3):227-246 Link to: Rev Esp Quimioter 2018; 31(3):247-256 Link to: Rev Esp Quimioter 2018; 31(3):247-256 Rev Esp Quimioter 2018; 31(3):247-256
Desplazarse hacia arriba Desplazarse hacia arriba Desplazarse hacia arriba

Utilizamos cookies propias y de terceros para garantizar el funcionamiento de la web, medir su uso y mejorar nuestros servicios. Puede aceptar todas las cookies, rechazar las no necesarias o configurar sus preferencias. Política de cookies

Configurar cookies

Necesarias para que la web funcione correctamente. No se pueden desactivar desde este panel.

Ayudan a medir el uso del sitio y mejorar sus contenidos.

Permiten publicidad, medición de campañas o personalización de anuncios.

Guardan preferencias o permiten contenido externo no necesario.